Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Here is Why Growth Investors Should Buy DexCom (DXCM) Now

by Zacks Equity Research

DexCom (DXCM) could produce exceptional returns because of its solid growth attributes.

Select Medical (SEM) Up 21% Year to Date: More Room to Run?

by Zacks Equity Research

Select Medical (SEM) is well-poised for growth on the back of improved patient volumes, an expanding healthcare portfolio and solid cash-generating abilities.

DexCom (DXCM) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

DexCom (DXCM) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, DexCom (DXCM) closed at $133.98, marking a +0.23% move from the previous day.

AngioDynamics (ANGO) Q4 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in fourth-quarter fiscal 2023.

3 Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Stryker (SYK) Launches Q Guidance System for Cranial Surgeries

by Zacks Equity Research

Stryker (SYK) launches its Q Guidance system with Cranial Guidance software, offering surgeons a comprehensive planning and guidance solution for complex cranial procedures.

Integra's (IART) Codman EVD Catheter Study Data Favorable

by Zacks Equity Research

Integra's (IART) Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus.

Cigna (CI) to Add Three Biosimilars to NPF, Enable Cost Savings

by Zacks Equity Research

Cigna (CI) plans to integrate three cost-effective biosimilars within NPF in a bid to offer varied treatment options for Americans and solidify its pharmacy business.

Here's Why You Should Add McKesson (MCK) to Your Portfolio

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Stryker (SYK) Launches Autonomous Guidance System for Surgeries

by Zacks Equity Research

Stryker's (SYK) fully autonomous Ortho Q Guidance system offers smart and streamlined workflow, leading to enhanced procedural speed and efficiency.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

DexCom's (DXCM) G7 CGM System Gets Nod From Health Canada

by Zacks Equity Research

DexCom's (DXCM) G7 CGM System's latest approval by Health Canada is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Reasons to Add Inari Medical (NARI) Stock to Your Portfolio

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

DexCom (DXCM) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Looking for a Growth Stock? 3 Reasons Why DexCom (DXCM) is a Solid Choice

by Zacks Equity Research

DexCom (DXCM) could produce exceptional returns because of its solid growth attributes.

Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Dexcom (DXCM) to Launch New Product in 2024, Ups Long-Term View

by Zacks Equity Research

Dexcom (DXCM) announces encouraging developments in 2024, including faster coverage for its products by private payers and new product launch for diabetic patients not on insulin.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Why Is Steris (STE) Down 0.9% Since Last Earnings Report?

by Zacks Equity Research

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.